Literature DB >> 28072464

Genistein and tyrphostin AG556 decrease ultra-rapidly activating delayed rectifier K+ current of human atria by inhibiting EGF receptor tyrosine kinase.

Guo-Sheng Xiao1, Yan-Hui Zhang1,2, Wei Wu2, Hai-Ying Sun2, Yan Wang1, Gui-Rong Li1,2.   

Abstract

BACKGROUND AND
PURPOSE: The ultra-rapidly activating delayed rectifier K+ current IKur (encoded by Kv 1.5 or KCNA5) plays an important role in human atrial repolarization. The present study investigates the regulation of this current by protein tyrosine kinases (PTKs). EXPERIMENTAL APPROACH: Whole-cell patch voltage clamp technique and immunoprecipitation and Western blotting analysis were used to investigate whether the PTK inhibitors genistein, tyrphostin AG556 (AG556) and PP2 regulate human atrial IKur and hKv1.5 channels stably expressed in HEK 293 cells. KEY
RESULTS: Human atrial IKur was decreased by genistein (a broad-spectrum PTK inhibitor) and AG556 (a highly selective EGFR TK inhibitor) in a concentration-dependent manner. Inhibition of IKur induced by 30 μM genistein or 10 μM AG556 was significantly reversed by 1 mM orthovanadate (a protein tyrosine phosphatase inhibitor). Similar results were observed in HEK 293 cells stably expressing hKv 1.5 channels. On the other hand, the Src family kinase inhibitor PP2 (1 μM) slightly enhanced IKur and hKv 1.5 current, and the current increase was also reversed by orthovanadate. Immunoprecipitation and Western blotting analysis showed that genistein, AG556, and PP2 decreased tyrosine phosphorylation of hKv 1.5 channels and that the decrease was countered by orthovanadate. CONCLUSION AND IMPLICATIONS: The PTK inhibitors genistein and AG556 decrease human atrial IKur and cloned hKv 1.5 channels by inhibiting EGFR TK, whereas the Src kinase inhibitor PP2 increases IKur and hKv 1.5 current. These results imply that EGFR TK and the soluble Src kinases may have opposite effects on human atrial IKur .
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28072464      PMCID: PMC5323513          DOI: 10.1111/bph.13710

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  65 in total

Review 1.  Regulation of ion channels by protein tyrosine phosphorylation.

Authors:  M J Davis; X Wu; T R Nurkiewicz; J Kawasaki; P Gui; M A Hill; E Wilson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-11       Impact factor: 4.733

Review 2.  Tyrphostins and other tyrosine kinase inhibitors.

Authors:  Alexander Levitzki; Eyal Mishani
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

3.  Genistein and tyrphostin AG556 inhibit inwardly-rectifying Kir2.1 channels expressed in HEK 293 cells via protein tyrosine kinase inhibition.

Authors:  De-Yong Zhang; Wei Wu; Xiu-Ling Deng; Chu-Pak Lau; Gui-Rong Li
Journal:  Biochim Biophys Acta       Date:  2011-05-06

4.  Inhibition of Kv4.3 by genistein via a tyrosine phosphorylation-independent mechanism.

Authors:  Hee Jae Kim; Hye Sook Ahn; Bok Hee Choi; Sang June Hahn
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-09       Impact factor: 4.249

5.  Genistein inhibits slow component delayed-rectifier K currents via a tyrosine kinase-independent pathway.

Authors:  T Washizuka; M Horie; K Obayashi; S Sasayama
Journal:  J Mol Cell Cardiol       Date:  1998-12       Impact factor: 5.000

6.  EGFR tyrosine kinase regulates human small-conductance Ca2+-activated K+ (hSKCa1) channels expressed in HEK-293 cells.

Authors:  Wei Wu; Hai-Ying Sun; Xiu-Ling Deng; Gui-Rong Li
Journal:  Biochem J       Date:  2013-05-15       Impact factor: 3.857

7.  Aging and muscle fiber type alter K+ channel contributions to the myogenic response in skeletal muscle arterioles.

Authors:  Lori S Kang; SeJeong Kim; James M Dominguez; Amy L Sindler; Gregory M Dick; Judy M Muller-Delp
Journal:  J Appl Physiol (1985)       Date:  2009-04-30

8.  Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation.

Authors:  J H Hanke; J P Gardner; R L Dow; P S Changelian; W H Brissette; E J Weringer; B A Pollok; P A Connelly
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

Review 9.  I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.

Authors:  Juan Tamargo; Ricardo Caballero; Ricardo Gómez; Eva Delpón
Journal:  Expert Opin Investig Drugs       Date:  2009-04       Impact factor: 6.206

10.  Differential effects of tyrosine kinase inhibitors on volume-sensitive chloride current in human atrial myocytes: evidence for dual regulation by Src and EGFR kinases.

Authors:  Xin-Ling Du; Zhan Gao; Chu-Pak Lau; Shui-Wah Chiu; Hung-Fat Tse; Clive M Baumgarten; Gui-Rong Li
Journal:  J Gen Physiol       Date:  2004-03-15       Impact factor: 4.086

View more
  3 in total

1.  Genistein and tyrphostin AG556 decrease ultra-rapidly activating delayed rectifier K+ current of human atria by inhibiting EGF receptor tyrosine kinase.

Authors:  Guo-Sheng Xiao; Yan-Hui Zhang; Wei Wu; Hai-Ying Sun; Yan Wang; Gui-Rong Li
Journal:  Br J Pharmacol       Date:  2017-02-09       Impact factor: 8.739

2.  Noradrenaline up-regulates volume-regulated chloride current by PKA-independent cAMP/exchange protein activated by cAMP pathway in human atrial myocytes.

Authors:  Guo-Sheng Xiao; Yan-Hui Zhang; Yan Wang; Hai-Ying Sun; Clive M Baumgarten; Gui-Rong Li
Journal:  Br J Pharmacol       Date:  2018-07-08       Impact factor: 8.739

3.  Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.

Authors:  Jing Gao; Rongmu Xia; Jianbo Chen; Jing Gao; Xianyang Luo; Chunlin Ke; Caihong Ren; Jiayi Li; Yanjun Mi
Journal:  Aging (Albany NY)       Date:  2020-04-10       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.